Matches in Wikidata for { <http://www.wikidata.org/entity/Q90602567> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- Q90602567 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q90602567 description "im Oktober 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90602567 description "scientific article published on 08 October 2019" @default.
- Q90602567 description "wetenschappelijk artikel" @default.
- Q90602567 description "наукова стаття, опублікована 8 жовтня 2019" @default.
- Q90602567 name "Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study" @default.
- Q90602567 name "Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study" @default.
- Q90602567 type Item @default.
- Q90602567 label "Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study" @default.
- Q90602567 label "Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study" @default.
- Q90602567 prefLabel "Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study" @default.
- Q90602567 prefLabel "Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study" @default.
- Q90602567 P1433 Q90602567-35EBE5F5-367E-4D5B-B310-FF3752051A91 @default.
- Q90602567 P1476 Q90602567-23F59A49-FD00-4095-8A29-4585FA4224CB @default.
- Q90602567 P2093 Q90602567-1FE673CC-54C3-484E-B74C-3F91709BDF98 @default.
- Q90602567 P2093 Q90602567-30EC8E33-1903-4882-A9D6-835487044151 @default.
- Q90602567 P2093 Q90602567-3613217B-2666-416D-890A-E692B139A9A0 @default.
- Q90602567 P2093 Q90602567-461759D6-0B76-4C2A-A720-E0248016C95C @default.
- Q90602567 P2093 Q90602567-5DE53086-E46C-4056-90DB-38C1827C9441 @default.
- Q90602567 P2093 Q90602567-9D1722CC-A537-495C-9D8F-98F658E72D49 @default.
- Q90602567 P2093 Q90602567-B30180C8-D05D-4AF6-A388-4BDC09B84A5A @default.
- Q90602567 P2093 Q90602567-B88C20FC-826D-4278-85EC-CD99ABF50E67 @default.
- Q90602567 P2093 Q90602567-C4C87F8C-B392-4ACE-A5F0-C9262E69FFF8 @default.
- Q90602567 P2093 Q90602567-D27BD21C-2C3F-45DA-BB9F-A7C3A650A88D @default.
- Q90602567 P2093 Q90602567-DF5C0303-A4E1-41E4-8A2B-ED948C63E948 @default.
- Q90602567 P2093 Q90602567-E6B77904-9FDE-4519-8134-77FD48375AD2 @default.
- Q90602567 P2093 Q90602567-F1448EC5-3024-4585-99EC-24F3FEE309B7 @default.
- Q90602567 P2093 Q90602567-F58B9596-E643-46BB-8536-59B21BF85E57 @default.
- Q90602567 P304 Q90602567-76DC07E6-865F-424C-B0E8-7482030435E9 @default.
- Q90602567 P31 Q90602567-7F1B120D-C23E-4075-98DB-FF1E28776FE8 @default.
- Q90602567 P356 Q90602567-C123F889-5C35-4A4F-A757-94A69DDC7D5D @default.
- Q90602567 P433 Q90602567-9D5F27E1-7BD5-45F2-B78B-3222F53B2BE0 @default.
- Q90602567 P478 Q90602567-535FF92A-AD9F-40CA-B74C-F290EBF602DB @default.
- Q90602567 P50 Q90602567-11CAA568-70CF-4B78-A652-CDBC9646CDC3 @default.
- Q90602567 P50 Q90602567-13148C7E-AF6D-4264-A51D-3F008995B71E @default.
- Q90602567 P50 Q90602567-6803CF57-2A52-4F50-8B8D-2AD9299CC4C3 @default.
- Q90602567 P50 Q90602567-72CB9F63-6F70-411E-9AC9-0390B1DB9A87 @default.
- Q90602567 P50 Q90602567-7BD2B81D-4587-4A51-A4C8-349C84CDE7BC @default.
- Q90602567 P50 Q90602567-9AEBC81C-6D8B-45B5-8D7A-7FBD4D80BDE1 @default.
- Q90602567 P50 Q90602567-AC1838B3-CB87-470C-ADE2-8ADCD13D74BA @default.
- Q90602567 P50 Q90602567-AC76B794-15FD-4DA2-BB1F-A72E5AF2398B @default.
- Q90602567 P577 Q90602567-9EB3298A-11CC-4A98-9FB0-F272D165D8BA @default.
- Q90602567 P698 Q90602567-68652670-11EB-4C0C-BEA2-549D3FDD3CFE @default.
- Q90602567 P921 Q90602567-B5C77C2D-B358-4824-A1E9-63E58238AA42 @default.
- Q90602567 P356 PBC.28032 @default.
- Q90602567 P698 31595663 @default.
- Q90602567 P1433 Q15754342 @default.
- Q90602567 P1476 "Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study" @default.
- Q90602567 P2093 "Alicia Castaneda-Heredia" @default.
- Q90602567 P2093 "Annick Devos" @default.
- Q90602567 P2093 "Arnauld Verschuur" @default.
- Q90602567 P2093 "European consortium Innovative Therapies for Children with Cancer (ITCC)" @default.
- Q90602567 P2093 "Gilles Vassal" @default.
- Q90602567 P2093 "Hervé Rubie" @default.
- Q90602567 P2093 "Kieran McHugh" @default.
- Q90602567 P2093 "Marie-Cecile Le Deley" @default.
- Q90602567 P2093 "Nadège Corradini" @default.
- Q90602567 P2093 "Pascal Chastagner" @default.
- Q90602567 P2093 "Pierre Leblond" @default.
- Q90602567 P2093 "Raphael Calmon" @default.
- Q90602567 P2093 "Riccardo Riccardi" @default.
- Q90602567 P2093 "Timothy Jaspan" @default.
- Q90602567 P304 "e28032" @default.
- Q90602567 P31 Q13442814 @default.
- Q90602567 P356 "10.1002/PBC.28032" @default.
- Q90602567 P433 "1" @default.
- Q90602567 P478 "67" @default.
- Q90602567 P50 Q37830644 @default.
- Q90602567 P50 Q57069863 @default.
- Q90602567 P50 Q57151651 @default.
- Q90602567 P50 Q89074677 @default.
- Q90602567 P50 Q90043668 @default.
- Q90602567 P50 Q90394646 @default.
- Q90602567 P50 Q90394778 @default.
- Q90602567 P50 Q90602561 @default.
- Q90602567 P577 "2019-10-08T00:00:00Z" @default.
- Q90602567 P698 "31595663" @default.
- Q90602567 P921 Q1333608 @default.